273 related articles for article (PubMed ID: 16759047)
1. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
3. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
4. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
5. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
[TBL] [Abstract][Full Text] [Related]
6. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.
Viard JP; Fagard C; Chaix ML; Rouzioux C; Bouteloup V; Bentata M; de Verdière NC; Pahlavan G; Weiss L; Lévy Y; Chêne G;
AIDS; 2009 Jul; 23(11):1383-8. PubMed ID: 19461505
[TBL] [Abstract][Full Text] [Related]
7. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
[TBL] [Abstract][Full Text] [Related]
8. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.
Raffi F; Katlama C; Saag M; Wilkinson M; Chung J; Smiley L; Salgo M
Clin Infect Dis; 2006 Mar; 42(6):870-7. PubMed ID: 16477567
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
[TBL] [Abstract][Full Text] [Related]
10. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
[TBL] [Abstract][Full Text] [Related]
11. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
[TBL] [Abstract][Full Text] [Related]
13. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694
[TBL] [Abstract][Full Text] [Related]
14. Use of darunavir and enfuvirtide in a pregnant woman.
Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
[TBL] [Abstract][Full Text] [Related]
15. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
[TBL] [Abstract][Full Text] [Related]
16. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
[TBL] [Abstract][Full Text] [Related]
17. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
[TBL] [Abstract][Full Text] [Related]
18. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
20. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
Aquaro S; D'Arrigo R; Svicher V; Perri GD; Caputo SL; Visco-Comandini U; Santoro M; Bertoli A; Mazzotta F; Bonora S; Tozzi V; Bellagamba R; Zaccarelli M; Narciso P; Antinori A; Perno CF
J Antimicrob Chemother; 2006 Oct; 58(4):714-22. PubMed ID: 16891628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
